YOLFTbeta
Lytix Biopharma AS

Lytix Biopharma AS

LYTIX · OL · Healthcare / Biotechnology

9.58NOK-0.22 (-2.24%)

Price History

Full chart

Market Stats

Previous Close9.80
Open9.80
Day Range8.66 – 9.80
52-Week Range6.94 – 11.90
Volume10.70K
Market Cap636.73M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.34
Dividend Yield0.00%
Beta-0.50
50-Day Avg8.28
200-Day Avg9.41

About

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is ruxotemitide, an oncolytic molecule that is developed for intratumoral injections, which is in Phase III clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma; and NeoLIPA Phase II study in combination with pembrolizumab. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a partnership with Verrica Pharmaceuticals Inc. for the development and commercialization of ruxotemitide for the treatment of all malignant and pre-malignant dermatological indications. Lytix Biopharma ASA was founded in 2003 and is based in Oslo, Norway.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Oystein Rekdal Ph.D.
  • Employees14
  • HeadquartersSandakerveien 138, Oslo, Norway, 0484, Norway
  • Websitehttps://www.lytixbiopharma.com

Leadership

  • Dr. Oystein Rekdal Ph.D.Co-Founder & CEO
  • Mr. Gjest Breistein M.Sc.Chief Financial Officer
  • Dr. Mette Husbyn Ph.D.Chief Technology Officer
  • Dr. Baldur Sveinbjørnsson Ph.D.Chief Scientific Officer
  • Ms. Renee Christine AmundsenChief Operating Officer
  • Mr. Ole Peter NordbyHead of IR & Communication Manager
  • Jacqueline EarabinoHead of Clinical Operations
  • Dr. Ahmed Bouzidi Ph.D.Senior VP of Business Development
  • Mr. Timothy F. Herpin M.B.A., Ph.D.Chief Business Officer

Financials

Income Statement

Currency: NOK2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.06M337.00K310.00K3.00K17.00K1.41M3.99M11.13M0
Growth (%)--68.18%-8.01%-99.03%+466.67%+8188.24%+183.25%+178.98%-100.00%
Operating Income-63.83M-62.37M-33.76M-42.37M-48.02M-65.69M-96.78M-95.90M-64.03M
Operating Margin-6027.38%-18506.82%-10890.65%-1412400.00%-282452.94%-4662.53%-2425.08%-861.29%-
EBITDA--62.36M---48.05M-55.92M-86.88M-93.22M-58.77M
EBITDA Margin--18505.04%---282623.53%-3968.84%-2176.87%-837.29%-
Net Income-63.36M-61.52M-33.23M-42.09M-48.05M-56.01M-87.90M-94.27M-59.98M
Net Income Margin-5982.63%-18253.71%-10718.39%-1402933.33%-282641.18%-3974.88%-2202.38%-846.64%-
R&D-39.90M14.02M16.01M28.82M50.97M63.17M72.56M13.80M
R&D as % of Total Revenue-11839.17%4522.90%533600.00%169511.76%3617.74%1582.74%651.74%-
Interest Expense00003.00K55.00K56.00K126.00K211.00K
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%17.65%3.90%1.40%1.13%-

Balance Sheet

Currency: NOK2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets47.09M58.90M17.43M32.62M202.96M152.02M63.87M146.53M81.52M
Total Liabilities35.30M17.85M3.85M12.73M13.34M16.89M12.55M38.64M19.77M
Total Equity11.79M41.05M13.58M19.89M189.62M135.13M51.32M107.89M61.75M
Cash34.96M48.87M12.05M27.15M197.28M94.55M25.79M129.31M10.60M

Cash Flow

Currency: NOK2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-69.67M-72.62M-36.82M-24.35M-44.90M-52.10M-95.97M-70.37M-59.85M
Investing Cash Flow-104.00K0-50.76M-50.76M-50.76M-50.76M29.73M24.69M-59.43M
Financing Cash Flow87.09M87.28M-5.00K40.00M213.73M133.00K-943.00K149.11M-908.00K
Capital Expenditure00154.00K154.00K154.00K154.00K49.00K00
Free Cash Flow--72.62M-36.82M-24.35M-44.90M-52.26M-96.02M-70.37M-59.85M
FCF to OCF-100.00%100.00%100.00%100.00%100.30%100.05%100.00%100.00%

Earnings

Report DateJun 30, 2021Feb 17, 2022Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Aug 31, 2023Sep 30, 2023Feb 28, 2024May 30, 2024Aug 29, 2024Nov 19, 2024Feb 13, 2025May 15, 2025Aug 28, 2025Feb 12, 2026Mar 31, 2026Aug 27, 2026Nov 11, 2026
EPS Estimate---------0.80-0.70----------
EPS Actual-0.32-0.42-0.39-0.03-0.28-0.73-0.49-0.78-0.45-0.46-0.45-0.48-0.46-0.54-0.19-0.07-0.27-0.34-0.35-
Surprise--------43.75%34.29%----------
Timing-After-hours-----Pre-market-After-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-market

Key Statistics & Ratios

Market Cap636.73M
Enterprise Value564.03M
Trailing P/E0.00
Forward P/E0.00
Price / Sales780.49
Price / Book7.55
EPS-1.34
Book Value1.13
Revenue (TTM)377.00K
Gross Profit (TTM)377.00K
EBITDA-99.02M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-107.13%
Return on Assets-58.83%
Shares Outstanding76.90M
Shares Float40.23M
Beta-0.50
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Jan 9, 20261485:1478